Trial Profile
A Study to Evaluate the Efficacy of Rh-Endostatin (Endostar) in Combination With Icotinib for Advanced Non-Small Cell Lung Cancer With EGFR Mutations
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 06 Nov 2021
Price :
$35
*
At a glance
- Drugs Endostatin (Primary) ; Icotinib (Primary)
- Indications Non-small cell lung cancer
- Focus Therapeutic Use
- 07 Jun 2016 Status changed from recruiting to completed, as per an abstract presented at the 52nd Annual Meeting of the American Society of Clinical Oncology.
- 07 Jun 2016 Results presented at the 52nd Annual Meeting of the American Society of Clinical Oncology
- 19 Mar 2015 Status changed from not yet recruiting to recruiting as reported by ClinicalTrials.gov record.